ACIU | tickerfilter.com

Fundamental analysis

29%

Profitability 25%

Dept financing 3%

Liquidity 50%

Performance 35%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

3.80%

1 Month

-17.17%

3 Months

-37.88%

6 Months

-45.33%

1 Year

-31.67%

2 Year

-15.46%

Key data

Stock price

$1.64

P/E Ratio

0.00

DAY RANGE

$1.62 - $1.68

EPS

-$0.28

52 WEEK RANGE

$1.43 - $4.98

52 WEEK CHANGE

-$31.67

MARKET CAP

418.102 M

YIELD

N/A

SHARES OUTSTANDING

98.940 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-12-2025

BETA

1.49

PUBLIC FLOAT

AVERAGE 10 VOLUME

$168,451

AVERAGE 30 VOLUME

$182,830

Company detail

CEO: Andrea Pfeifer
Region: US
Website: acimmune.com
Employees: 140
IPO year: 2016

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

AC Immune SA discovers, designs, and develops medicines and diagnostic products. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease. It is also developing ACI-24, an anti-Abeta vaccine candidate, as well as completed Phase Ib clinical study for Down syndrome. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases.

ACIU - AC Immune SA